AKTS · CIK 0002035832
What Aktis Oncology, Inc. told the SEC could break it.
Aktis is early-stage and dependent on others at both ends of its business. It has no product revenue, and substantially all the revenue it has earned to date comes from work under a single Eli Lilly collaboration agreement, so that one relationship effectively is its top line for now. It is also fabless — owning no cGMP manufacturing — and relies on third-party contract manufacturers for clinical and future commercial production of its targeted-alpha radiopharmaceutical candidates, leaving supply exposed to those CMOs' compliance and capacity. Looking ahead, any approved product would face drug-pricing pressure from the Inflation Reduction Act, including Medicare Part D out-of-pocket caps, new manufacturer financial liability and price negotiation.
3 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Customer concentration
- substantially all revenue from the Eli Lilly Collaboration Agreementmedium
Pre-revenue from products; substantially all revenue to date is derived from work performed under the single Eli Lilly Collaboration Agreement.
“Substantially all of our revenue to date has been derived from the work performed under the Collaboration Agreement.”
SEC filing →As of 2026
Supplier concentration
- fabless; reliant on third-party CMOs for radiopharmaceutical supplymedium
Owns no cGMP manufacturing; relies on third parties for clinical and (future) commercial production of its targeted-alpha radiopharmaceutical candidates (e.g. [225Ac]Ac-AKY-1189), exposing supply to CMO compliance/capacity risk.
“Until we are able to establish our own cGMP manufacturing facility, we expect to continue to rely on third parties for the production of clinical quantities of our product candidates, and expect to rely in the future on third parties for the production of commercial quantities.”
SEC filing →As of 2026
Regulatory & policy
- IRA Medicare drug-pricing reformslow
Future product economics exposed to the Inflation Reduction Act of 2022 — Medicare Part D out-of-pocket caps, new manufacturer financial liability, and Medicare price negotiation.
“For example, on August 16, 2022, the Inflation Reduction Act of 2022, or IRA, was signed into law by President Biden. The IRA includes several provisions that may impact pharmaceutical companies to varying degrees, including provisions that create a ,000 out-of-pocket cap for Medicare Part D beneficiaries; impose new manufacturer financial liability on all drugs in Medicare Part D.”
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
“The Collaboration Agreement requires Eli Lilly to use commercially reasonable efforts to develop and commercialize a licensed product from a research program in certain markets and through satisfaction of certain criteria.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch